OakChart

Traws Pharma Inc

TRAWHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 2:25 PM ET

0.2450+0.0200 (8.89%)
2026-11-11 20:26 CET
Market cap
3.46 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-21.57 USD m
Free cash flow, TTM
-16.85 USD m
EPS diluted, TTM
-2.31
P/E
-
Compare

Price

TRAW against its 20, 50 and 200-day averages
2050200beatmiss
1.002.003.0044.7M89.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TRAWclose 0.2520-day 0.3150-day 0.44200-day 1.080.2552w high

92.4% under the 52-week high of 3.23 on 11 May 2026. 52-week low 0.22 on 5 Nov 2026. Last 15 sessions, 75.8% high to low

Profile

TRAW
52-week range, 1% of the way up
0.223.23

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Employees7
IPOJul 25, 2013
Beta1.69
ATR, 14d0.04
Rel volume0.17
Short float6.30%
Insider own29.34%
Inst own27.23%

Snapshot

6 groups

Valuation

Index-
Market Cap3.77M
Enterprise Value-1.25M
Income-21.57M
Sales0.00M
Book/sh0.11
Cash/sh0.33
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees7
IPOJul 25, 2013

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.21
P/C0.75
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.93
Current Ratio0.93
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.31
EPS next Y-1.24
EPS next Q-0.20
EPS this Y-246.34%
EPS next Y-2.92%
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y131.12% 64.59%
EPS Y/Y TTM83.59%
Sales Y/Y TTM-100.00%
EPS Q/Q-22.55%
Sales Q/Q-100.00%
EarningsAug 14 AMC
EPS/Sales Surpr.52.24% -

Ownership

Insider Own29.34%
Insider Trans0.00%
Inst Own27.23%
Inst Trans12.50%
ROA-159.21%
ROE-433.36%
ROIC-1275.34%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-22.07%
SMA50-44.25%
SMA200-77.32%
Trades-

Technical

Shs Outstand15.26M
Shs Float10.86M
Short Float6.30%
Short Ratio1.18
Short Interest0.68M
52W High3.23 -92.41%
52W Low0.22 12.03%
Volatility17.25% 11.00%
ATR (14)0.04
RSI (14)29.80
Beta1.69
Rel Volume0.17
Avg Volume580.29K
Volume78,061

Performance

Perf Week-8.79%
Perf Month-40.26%
Perf Quarter-59.17%
Perf Half Y-85.76%
Perf YTD-78.32%
Perf Year-87.04%
Perf 3Y-98.47%
Perf 5Y-99.72%
Perf 10Y-100.00%
Recom3.00
Target Price1.00
Prev Close0.22
Price0.25
Change %8.89%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Jun 15, 2026DowngradeLLadenburg ThalmannBuy → Neutral
Dec 03, 2025InitiatedHH.C. WainwrightBuy$8+3,165.3%
Mar 01, 2022InitiatedLLadenburg ThalmannBuy$7+2,757.1%
May 18, 2021InitiatedGGuggenheimBuy$4+1,532.7%
Mar 01, 2018ReiteratedHH.C. WainwrightBuy$6 → $7.50+2,961.2%
Jan 17, 2018DowngradeMMaxim GroupBuy → Hold
Oct 09, 2017InitiatedHH.C. WainwrightBuy$6+2,349.0%
Apr 27, 2017InitiatedLLaidlawBuy$10+3,981.6%
Jul 01, 2015UpgradePPiper JaffrayNeutral → Overweight
May 05, 2015InitiatedHH.C. WainwrightBuy$6+2,349.0%

Peers

Mkt cap
TickerCompanyMkt cap
COCPCocrystal Pharma Inc19.84M
AVIRAtea Pharmaceuticals Inc340.09M
NNVCNanoViricides Inc35.74M
ENTAEnanta Pharmaceuticals Inc338.15M
SXTP60 Degrees Pharmaceuticals Inc1.79M
VIRVir Biotechnology Inc2.25B
ALGSAligos Therapeutics Inc15.36M
IMRNImmuron Limited ADR7.51M
SPROSpero Therapeutics Inc59.40M
ARMPArmata Pharmaceuticals Inc140.36M

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
ORBIMED ADVISORS LLC10% OwnerApr 16 '26Buy1.67597,729998,2071,203,250Apr 28 09:41 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 198

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-0.160-0.335-0.1600.000.002
2026Q12026-05-15-0.530-0.560-0.6680.000.001
2025Q42026-04-15-0.820-1.224-1.0010.000.002
2025Q32025-11-13-0.340--0.4490.00--
2025Q22025-08-14-0.110--0.1572.73--
2025Q12025-05-152.090-2.9750.06--
2024Q42025-03-31101.35--8.1800.06--
2024Q32024-11-14-8.810-6.250-8.8140.060.061
2024Q22024-08-15-121.75--121.630.06--
2024Q12024-05-16-6.000-5.875-5.9200.060.062
2023Q42024-04-01-4.750-6.333-4.9800.060.073
2023Q32023-11-14-5.750-7.250-5.6410.060.074
2023Q22023-08-10-5.000-7.813-5.0650.060.074
2023Q12023-05-15-7.000-7.438-6.8880.060.084
2022Q42023-03-16-6.500-6.938-6.4750.050.084
2022Q32022-11-14-6.500-5.313-6.4520.060.074

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-558.75-658.75-560.582.182.21
2020FY-52.500-51.563-54.2060.230.21
2021FY-24.000-23.000-24.0060.230.23
2022FY-22.750-23.125-22.6750.230.21
2023FY-22.500-23.917-22.5690.230.22
2024FY-35.210--106.70.23-
2025FY0.8200.6900.8202.792.80
2026FY--1.200--0.00
2027FY--1.235--0.00
2028FY--0.600--0.00
2029FY--0.340--11.30
2030FY-0.020--39.10

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-172000.000.000.00
2026Q3S2026-08-152000.000.000.00
2026Q3S2026-08-142000.000.000.00
2026Q3S2026-05-192000.000.000.00
2026Q3S2026-05-151000.000.000.00
2026Q3S2026-04-161000.000.000.00
2026Q3S2026-01-292000.000.000.00
2026Q3S2025-12-021000.000.000.00
2026Q3R2026-10-31200-0.21-0.21-0.20
2026Q3R2026-08-17211-0.21-0.21-0.20
2026Q3R2026-08-15220-0.22-0.36-0.08
2026Q3R2026-08-14220-0.22-0.36-0.08
2026Q3R2026-06-17220-0.22-0.36-0.08
2026Q3R2026-06-12220-0.28-0.36-0.20

Estimate history

EPS, annual-15056.944-1870.691-560.58-54.206-24.006-22.675-22.569-106.7031.094-2.3093
Period201720182019202020212022202320242025TTM
EPS, quarterly-121.631-8.814-8.182.975-0.157-0.449-1.001-0.668-0.192
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.7871.2282.1830.2310.2260.2260.2260.2262.790
Period201720182019202020212022202320242025TTM
Sales, quarterly0.0570.0570.0560.0572.7330000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0020.0150.2960.4960.8360.8370.843.6589.07515.272
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.0123.0333.6585.0837.0767.1389.07510.16915.272
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.002.790.230.230.230.230.232.181.23
Cost of Goods Sold Incl. D&A0.150.060.010.020.010.01---
Gross Profit-0.152.730.210.210.210.21---
Selling, General and Administrative Excl. Other22.8020.6025.1220.5119.8416.7125.2123.8724.45
Research and Development13.3112.1412.8411.4111.397.2816.8915.5216.87
Other Operating Expense-1.410.0024.440.000.000.000.000.000.00
Operating Income-21.54-17.88-49.35-20.30-19.63-16.50-24.99-21.70-23.28
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.04-26.57117.460.000.00-0.320.21-0.06-1.60
Net Income Before Taxes-21.579.17-166.52-18.95-18.96-16.16-25.15-21.49-20.53
Income Taxes0.000.000.000.000.000.000.000.01-0.12
Consolidated Net Income-21.579.17-166.52-18.95-18.96-16.16-25.16-21.50-20.41
Net Income From Continuing Operations-21.579.17-166.52-18.95-18.96-16.16-25.16-21.50-20.57
Net Income-21.579.17-166.52-18.95-18.96-16.16-25.16-21.50-20.57
EPS (Recurring)-1.36-1.12-54.02-22.57-22.68-24.34-53.89-561.73-1,972.34
EPS (Basic, Before Extraordinaries)-2.311.11-106.70-22.57-22.68-24.01-54.21-560.58-1,870.69
EPS (Diluted)-2.311.09-106.70-22.57-22.68-24.01-54.21-560.58-1,870.69
EBITDA-21.40-17.81-49.34-20.28-19.61-16.48-24.98-21.68-23.23
Non-Operating Income (Expense)0.010.480.291.350.660.010.050.141.15
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.910.731.391.301.160.580.370.770.87
Price To Sales Ratio-3.4061.3269.2459.74189.92350.932.527.09
Gross Margin-97.8194.6992.9293.8193.81---
Operating Margin--640.68-21,835.40-8,981.42-8,684.51-7,299.12-10,819.48-994.00-1,895.93
Net Margin-328.67-73,682.74-8,384.07-8,391.15-7,151.77-10,890.48-985.02-1,675.33
Shares Outstanding15.279.073.660.840.840.840.500.300.02
Market Capitalization3.463.4626.8715.6613.5153.2886.6142.5811.97

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.002.730.060.060.06
Cost of Goods Sold Incl. D&A0.040.040.040.010.000.000.000.00
Gross Profit-0.04-0.04-0.04-0.012.730.060.050.06
Selling, General and Administrative Excl. Other4.546.907.324.043.985.265.338.59
Research and Development1.104.875.042.312.292.501.865.11
Other Operating Expense-1.410.000.000.000.000.0024.440.00
Operating Income-3.17-6.95-7.37-4.05-1.25-5.20-29.72-8.54
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense-0.210.160.090.00-0.15-26.510.000.00
Net Income Before Taxes-3.05-7.11-7.44-3.96-0.9221.49-29.92-8.47
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-3.05-7.11-7.44-3.96-0.9221.49-29.92-8.47
Net Income From Continuing Operations-3.05-7.11-7.44-3.96-0.9221.49-29.92-8.47
Net Income-3.05-7.11-7.44-3.96-0.9221.49-29.92-8.47
EPS (Recurring)-0.20-0.66-0.99-0.45-0.170.41-8.18-8.81
EPS (Basic, Before Extraordinaries)-0.19-0.67-1.00-0.45-0.163.08-8.18-8.81
EPS (Diluted)-0.19-0.67-1.00-0.45-0.162.98-8.18-8.81
EBITDA-3.13-6.90-7.32-4.04-1.25-5.20-29.71-8.53
Non-Operating Income (Expense)-0.09-0.000.010.100.190.18-0.210.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.820.630.330.140.100.160.330.34
Price To Earnings Ratio-0.080.050.12----
Price To Sales Ratio-7.133.015.742.9773.18143.7425.02
Gross Margin----99.9698.2596.4396.49
Operating Margin-----45.70-9,128.07-53,064.29-14,975.44
Net Margin-----33.4837,701.75-53,432.14-14,868.42
Shares Outstanding15.2710.179.077.147.085.083.663.03
Market Capitalization3.4614.629.0313.078.2411.5826.8717.79

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments3.8221.3420.8238.7655.0719.0222.7316.974.02
Short Term Receivables3.791.760.020.030.030.040.100.040.06
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.361.851.820.560.330.720.650.760.82
Total Current Assets7.9824.9522.6639.3555.4319.7823.4717.774.90
Net Property, Plant & Equipment0.010.010.020.020.040.050.050.010.06
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets2.53--0.000.000.000.000.000.00
Other Assets0.100.000.000.000.010.150.150.150.01
Total Assets10.6224.9622.6839.3755.4819.9923.6717.924.98
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.000.000.000.00
Accounts Payable5.658.195.623.862.764.834.274.046.19
Other Current Liabilities5.493.353.604.193.365.194.024.403.79
Total Current Liabilities11.1511.539.228.056.1210.028.298.449.98
Long Term Debt0.000.000.000.000.000.000.000.000.00
Provision for Risks Charges0.0042.490.000.000.000.000.000.000.00
Other Liabilities0.102.562.793.023.243.793.814.105.86
Total Liabilities11.2556.5912.0111.069.3613.8112.1012.5415.84
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-0.63-31.6310.6728.3146.126.1711.575.39-11.69
Total Shareholders Equity-0.63-31.6310.6728.3146.126.1711.575.39-11.69
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.83
Total Equity-0.63-31.6310.6728.3146.126.1711.575.39-10.86
Total Liabilities & Stockholders Equity10.6224.9622.6839.3755.4819.9923.6717.924.98
Book Value Per Share-0.07-8.6512.7033.8255.1812.4539.04356.02-6,105.36
Tangible Book Value Per Share-0.35-8.6512.7033.8255.1812.4539.04356.02-6,105.36
Full-Time Employees7717171512192525
Price to Book Ratio2.03-13.221.080.401.1614.033.682.22-2.14
Return on Assets51.55-699.02-61.07-39.99-42.84-115.24-103.39-179.66-170.79
Return on Equity---97.22-50.96-61.81-283.48-253.56--
Return on Invested Capital---177.55-66.99-35.05-407.40-185.79-381.90-
Quick Ratio0.722.162.464.899.061.972.832.110.49
Current Ratio0.722.162.464.899.061.972.832.110.49

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-21.579.17-166.52-18.95-18.96-16.16-25.16-21.50-20.41
Depreciation0.150.060.010.020.010.010.010.010.06
Other Funds (Non Cash)1.95-25.84143.291.301.170.260.580.98-1.27
Funds from Operations-19.47-16.61-23.22-17.63-17.78-15.89-24.57-20.50-21.63
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital2.62-1.58-6.57-0.301.48-3.591.49-0.33-1.07
Cash from Operating Activities-16.85-18.18-29.79-17.93-16.29-19.49-23.07-20.83-22.70
Capital Expenditures-2.58-2.580.00-0.010.000.00-0.01-0.060.00
Net Assets From Acquisitions0.000.00-3.650.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-2.58-2.58-3.65-0.010.000.00-0.01-0.060.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock11.383.2033.980.000.0055.5619.3626.6535.66
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock11.383.2033.980.000.0055.5619.3626.6535.66
Proceedsfrom Stock Options11.373.1833.980.000.0055.049.0621.7635.07
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities11.383.2033.980.000.0055.5619.3626.6535.66
Exchange Rate Effect-0.010.05-0.020.01-0.02-0.030.03-0.01-0.01
Net Change in Cash-8.06-17.520.52-17.94-16.3136.05-3.705.7612.95
Free Cash Flow-16.85-18.18-29.79-17.95-16.29-19.49-23.09-20.89-22.70
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments5.023.133.826.4213.0815.94
Short Term Receivables3.451.693.791.991.321.65
Inventories0.000.000.000.000.000.00
Other Current Assets0.550.840.361.210.971.26
Total Current Assets9.025.677.989.6215.3718.86
Net Property, Plant & Equipment0.010.010.010.010.010.01
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets2.442.482.532.57--
Other Assets0.000.000.100.240.240.20
Total Assets11.478.1610.6212.4415.6219.06
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable6.337.675.655.114.767.66
Other Current Liabilities3.405.545.492.782.592.75
Total Current Liabilities9.7313.2111.157.897.3510.40
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.040.260.100.010.012.66
Total Liabilities9.7813.4711.257.907.3613.06
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1.69-5.31-0.634.548.266.00
Total Shareholders Equity1.69-5.31-0.634.548.266.00
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1.69-5.31-0.634.548.266.00
Total Liabilities & Stockholders Equity11.478.1610.6212.4415.6219.06
Book Value Per Share0.11-0.52-0.070.641.171.18
Tangible Book Value Per Share-0.05-0.77-0.350.281.171.18
Full-Time Employees--7---
Price to Book Ratio2.032.871.771.581.25-0.27
Return on Assets-159.21-142.7551.55-124.51-103.89-752.25
Return on Equity-433.36-5,639.19--1,059.63-248.20-2,331.25
Return on Invested Capital-180.60---87.17-11.07358.17
Quick Ratio0.930.430.721.222.091.81
Current Ratio0.930.430.721.222.091.81

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-3.05-7.11-7.44-3.96-0.9221.49
Depreciation0.040.040.040.010.000.00
Other Funds (Non Cash)0.600.790.420.14-0.04-26.35
Funds from Operations-2.41-6.27-6.98-3.81-0.95-4.86
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-5.093.694.22-0.20-5.02-0.58
Cash from Operating Activities-7.50-2.58-2.76-4.01-5.98-5.44
Capital Expenditures0.000.00-2.580.000.000.00
Net Assets From Acquisitions0.000.002.58-2.580.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.00-2.580.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock9.391.900.16-0.063.100.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock9.391.900.16-0.063.100.01
Proceedsfrom Stock Options9.391.900.15-0.063.09-0.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities9.391.900.16-0.063.100.01
Exchange Rate Effect-0.00-0.010.00-0.000.030.02
Net Change in Cash1.88-0.69-2.60-6.66-2.86-5.40
Free Cash Flow-7.50-2.58-2.76-4.01-5.98-5.44

Revenue breakdown

Total Pharmaceutical Preparations revenue2024: 226.00K 2025: 2.79M
United States2024: 226.00K 2025: 2.79M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.30%0.7M10.9M577.76K
2026-10-156.31%0.7M10.9M569.64K
2026-09-306.36%0.7M10.9M575.03K
2026-09-155.64%0.6M10.9M149.90K
2026-08-315.85%0.6M10.8M262.08K
2026-08-145.76%0.6M10.8M383.62K
2026-07-314.94%0.6M12.7M2.29M
2026-07-155.51%0.7M12.7M2.36M
2026-06-307.72%1.0M12.7M2.33M
2026-06-158.98%1.1M12.6M2.25M
2026-05-2912.04%1.4M11.4M2.17M
2026-05-1514.64%1.7M11.4M2.09M
2026-04-305.38%0.6M10.4M160.28K
2026-04-156.66%0.4M6.1M169.37K
2026-03-316.76%0.4M6.1M193.36K
2026-03-137.50%0.5M6.1M289.28K
2026-02-278.54%0.5M6.1M302.73K
2026-02-138.65%0.5M6.1M445.95K
2026-01-308.30%0.5M6.1M443.94K
2026-01-158.73%0.5M6.1M404.63K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05DNotice of sales of securities on Form D (Regulation D)SEC
2026-10-26S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-10-238-KCurrent report2026-10-23SEC
2026-10-20DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-20DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-12-03SEC
2026-10-08PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-08SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-14SCHEDULE 13GSEC
2026-08-12SCHEDULE 13G/ASEC
2026-07-318-KCurrent report2026-07-29SEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-154Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-154Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-108-KCurrent report2026-07-10SEC
2026-07-10424B5SEC
2026-07-09EFFECTEffectiveness filing by commission orderSEC
2026-07-098-KCurrent report2026-07-08SEC
2026-07-07CORRESPSEC
2026-07-07UPLOADUpload SubmissionSEC
2026-07-01S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-04998.21K100
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
ORBIMED ADVISORS LLC7.94%
Ally Bridge Group5.19%
ADAGE CAPITAL PARTNERS GP, L.L.C.4.82%
ADAR1 Capital Management, LLC3.94%
Lynx1 Capital Management LP3.69%
Ikarian Capital, LLC3.15%
SPHERA FUNDS MANAGEMENT LTD.2.63%
VANGUARD CAPITAL MANAGEMENT LLC2.18%
JANE STREET GROUP, LLC1.43%
Alyeska Investment Group, L.P.1.08%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND2.12%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.17%
Fidelity Extended Market Index Fund0.48%
Fidelity Nasdaq Composite Index Fund0.11%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.10%
Fidelity Series Total Market Index Fund0.05%
Fidelity Total Market Index Fund0.05%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. TRAW. Cached 15 minutes.